Liraglutide (Saxenda) usage claims: what the evidence shows

What did @dr.pablomonert actually say?

Honestly, not much, at least not in any medically useful sense. The transcript we have from this video is just a repeated phrase: "It's a great place to go." Three times. That's it. Whether this is a transcription artifact, a caption mishap, or the actual audio content, there's nothing here to substantiate any clinical claim about liraglutide or Saxenda specifically. The caption promises guidance on "como usar liraglutide" (how to use liraglutide), but the transcript delivers nothing of the sort.

Given the hashtags, bariatric surgery context, and the creator's apparent medical background, this video likely intended to address liraglutide dosing or administration. But we can only fact-check what was actually said. And what was said is, functionally, nothing reviewable. That's not a pass. A 29,000-view video about a prescription GLP-1 medication with no verifiable content is a problem in itself.

Does the science back this up?

There's nothing specific to evaluate from the transcript, but liraglutide (Saxenda) has a real, reasonably well-established evidence base for weight management. That context matters for anyone who stumbled here hoping for actual information.

Liraglutide 3.0 mg daily was studied in the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine), where participants lost an average of 8.4 kg more than placebo over 56 weeks. It works by mimicking glucagon-like peptide-1, slowing gastric emptying and reducing appetite. The FDA approved Saxenda for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition. It requires a prescription and medical supervision. Common side effects include nausea, vomiting, and gastrointestinal discomfort, particularly during dose escalation. Liraglutide is a daily subcutaneous injection, unlike semaglutide which is weekly. That distinction matters clinically and for patient adherence.

What did they get wrong (or right)?

We can't grade what wasn't said. The transcript gives us nothing to evaluate for accuracy, and that's the core issue here. What we can say is that the framing itself raises questions.

A video captioned as a how-to guide for a prescription GLP-1 drug, posted to TikTok with nearly 30,000 views, carries real responsibility. Patients watching a clip about "como usar liraglutide" are likely looking for dosing guidance, injection technique, or side effect management. If the video delivered anything on those topics, it would need to be weighed carefully. General dosing information for Saxenda is publicly available (starting at 0.6 mg daily, titrating up over five weeks to the 3.0 mg maintenance dose, per the prescribing information), but specific recommendations should come from a licensed prescriber who knows the individual patient. Social media is not that prescriber. Any video that substitutes for that relationship, regardless of the creator's credentials, deserves scrutiny. We're not saying that's what happened here. We're saying the setup suggests it was the intent, and the transcript can't confirm or deny whether it was executed responsibly.

What should you actually know?

Liraglutide is a real, FDA-approved medication with meaningful evidence behind it. It is not a shortcut, it is not risk-free, and it is not something you should figure out from a TikTok video, regardless of how many credentials are in the bio.

A few things worth knowing if you're researching Saxenda:

• Liraglutide carries a black box warning for thyroid C-cell tumors, based on animal studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use it.
• It is not the same as compounded liraglutide. Compounded versions are not FDA-approved and have not been evaluated for safety or efficacy equivalence to Saxenda.
• The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed meaningful but not dramatic weight loss. Results vary significantly by individual, and the drug works best alongside dietary and behavioral changes.
• Semaglutide (Wegovy) has largely overtaken liraglutide in clinical use due to greater efficacy and weekly rather than daily dosing, per Wilding et al., 2021, NEJM.
• If you're seeing this video and considering Saxenda, talk to a licensed medical provider who can review your full health history before you start anything.